+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030- Product Image
Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030- Product Image
Sale

Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715523
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives navigating the pharmaceutical sector face an evolving landscape in antihypertensive drug development, shaped by stringent regulations, technological integration, supply chain pressures, and varying regional demands. To thrive, leaders need precise market intelligence that informs strategic growth, investment, and competitive positioning priorities.

Market Snapshot: Antihypertensive Drugs Market Growth and Trajectory

The antihypertensive drugs market grew from USD 25.76 billion in 2024 to USD 27.04 billion in 2025. It is expected to continue growing at a CAGR of 4.73%, reaching USD 34.01 billion by 2030. This expansion reflects growing global prevalence of hypertension, ongoing treatment innovation, and increased demand for patient-centric pharmaceutical solutions across both developed and emerging markets.

Scope & Segmentation of the Antihypertensive Drugs Market

  • Therapeutic Class: ACE inhibitors (enalapril, lisinopril, perindopril, ramipril), angiotensin receptor blockers (candesartan, irbesartan, losartan, telmisartan, valsartan), beta blockers (atenolol, bisoprolol, metoprolol, propranolol), calcium channel blockers (amlodipine, diltiazem, felodipine, verapamil), diuretics (loop, osmotic, potassium sparing, thiazide), renin inhibitors (aliskiren), and vasodilators (diazoxide, hydralazine, minoxidil).
  • Therapy Type: Monotherapy and combination therapy, including dual and triple combinations for managing resistant cases.
  • Administration Route: Injectable (intramuscular, intravenous, subcutaneous) and oral routes (capsules, oral solutions, powders, tablets).
  • Dosage Form: Capsules, injections, oral solutions, tablets support a range of care settings from acute intervention to long-term control.
  • Distribution Channel: Hospital pharmacies (private and public), online pharmacies (aggregators, direct to consumer), and retail pharmacies (chain, independent).
  • End Users: Clinics (primary and specialty), homecare settings (self-medication, supervised care), and hospitals (private, public).
  • Geographical Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (multiple key countries), and Asia-Pacific (China, India, Japan, Australia, and other major markets).
  • Company Analysis: Profiles and recent significant developments from major industry players, including Novartis AG, Pfizer Inc., AstraZeneca PLC, and others.

Key Takeaways: Strategic Insights for Decision-Makers

  • Innovative treatment pathways leverage precision medicine and digital health platforms, supporting more personalized hypertension management and improved adherence.
  • Lifecycle management through new formulations and extended-release technologies extends product value for both legacy and pipeline therapies.
  • Strategic collaborations—especially between established pharmaceutical firms and technology partners—accelerate the launch of first-in-class mechanisms and digital adherence solutions.
  • Real-world evidence and robust pharmacovigilance programs enhance payer engagement, supporting reimbursement negotiations and distinguishing offerings.
  • Distinct regional regulations and healthcare infrastructure require flexible go-to-market strategies, including tailored access programs for underserved areas.
  • Segment attractiveness varies, with combination therapy and evolving oral delivery options meeting demand for flexible, effective hypertension control.

Tariff Impact: U.S. Market Adjustments Post-2025

The implementation of tariffs on key pharmaceutical imports into the United States from 2025 onward has introduced new cost challenges along the supply chain. Manufacturers are now diversifying sourcing strategies, growing domestic production capacities, and entering joint ventures for risk-sharing and sourcing flexibility. Payers are intensifying scrutiny of manufacturer transparency, while collaboration across the sector has spurred shared production and co-marketing arrangements, influencing procurement and market competition across U.S. channels.

Methodology & Data Sources

This report utilizes a multi-stage research process, synthesizing primary interviews with industry experts, healthcare providers, payers, and senior executives. Secondary sources include peer-reviewed journals, regulatory filings, and sector reports. Thematic coding and advanced statistical analysis support data triangulation and enhance validity.

Why This Report Matters

  • Equips leaders with actionable insights for portfolio optimization, assessing both mature and high-growth market segments.
  • Supports investment and partnership decisions through detailed breakdowns of regulations, competitive dynamics, and technology integration.
  • Facilitates market entry and expansion strategies adapted to local needs and future policy shifts.

Conclusion

Senior decision-makers can rely on this analysis to clarify risks, identify strategic opportunities, and guide sustainable growth in the global antihypertensive drugs market. Use these insights for informed planning, market navigation, and resource alignment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antihypertensive Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Ace Inhibitors
8.2.1. Enalapril
8.2.2. Lisinopril
8.2.3. Perindopril
8.2.4. Ramipril
8.3. Angiotensin Receptor Blockers
8.3.1. Candesartan
8.3.2. Irbesartan
8.3.3. Losartan
8.3.4. Telmisartan
8.3.5. Valsartan
8.4. Beta Blockers
8.4.1. Atenolol
8.4.2. Bisoprolol
8.4.3. Metoprolol
8.4.4. Propranolol
8.5. Calcium Channel Blockers
8.5.1. Amlodipine
8.5.2. Diltiazem
8.5.3. Felodipine
8.5.4. Verapamil
8.6. Diuretics
8.6.1. Loop
8.6.2. Osmotic
8.6.3. Potassium Sparing
8.6.4. Thiazide
8.7. Renin Inhibitors
8.7.1. Aliskiren
8.8. Vasodilators
8.8.1. Diazoxide
8.8.2. Hydralazine
8.8.3. Minoxidil
9. Antihypertensive Drugs Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.2.1. Dual Combination
9.2.2. Triple Combination
9.3. Monotherapy
10. Antihypertensive Drugs Market, by Administration Route
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
10.3. Oral
10.3.1. Capsules
10.3.2. Oral Solutions
10.3.3. Powders
10.3.4. Tablets
11. Antihypertensive Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsules
11.3. Injections
11.4. Oral Solutions
11.5. Tablets
12. Antihypertensive Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.2.1. Private Hospitals
12.2.2. Public Hospitals
12.3. Online Pharmacies
12.3.1. Aggregators
12.3.2. Direct To Consumer
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. Antihypertensive Drugs Market, by End Users
13.1. Introduction
13.2. Clinics
13.2.1. Primary Care Clinics
13.2.2. Specialty Clinics
13.3. Homecare
13.3.1. Self Medication
13.3.2. Supervised Care
13.4. Hospitals
13.4.1. Private Hospitals
13.4.2. Public Hospitals
14. Americas Antihypertensive Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antihypertensive Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antihypertensive Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Pfizer Inc.
17.3.3. AstraZeneca PLC
17.3.4. Sanofi S.A.
17.3.5. Merck & Co., Inc.
17.3.6. Boehringer Ingelheim International GmbH
17.3.7. Bayer AG
17.3.8. GlaxoSmithKline plc
17.3.9. Teva Pharmaceutical Industries Ltd.
17.3.10. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ENALAPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PERINDOPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RAMIPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CANDESARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY IRBESARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TELMISARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VALSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY AMLODIPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DILTIAZEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FELODIPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VERAPAMIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LOOP, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY POTASSIUM SPARING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THIAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALISKIREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HYDRALAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY MINOXIDIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DUAL COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRIPLE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY AGGREGATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SUPERVISED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 141. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 142. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 144. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 145. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 146. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 147. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 149. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 150. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 153. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 155. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 158. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 160. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 161. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 162. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 173. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 177. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 184. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 224. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 228. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 275. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 277. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 278. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 279. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 280. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 282. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 283. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 284. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 285. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 286. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 287. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 288. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 290. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 295. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 297. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 299. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 300. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 301. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 302. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 304. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 305. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 306. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 307. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 308. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 309. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 312. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 313. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 314. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 315. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 316. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 317. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 319. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 320. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 321. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 322. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 323. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antihypertensive Drugs market report include:
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 27.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.01 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032 - Product Image

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Antihypertensive Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Antihypertensive Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030 - Product Image

Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F - Product Image

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
North America ACE Inhibitors Market, By Country, Competition, Forecast & Opportunities, 2019-2029F - Product Image

North America ACE Inhibitors Market, By Country, Competition, Forecast & Opportunities, 2019-2029F

  • Report
  • 136 Pages
  • North America
From

About the Antihypertensive Market

The Antihypertensive market is a subset of the Cardiovascular Drugs market, which focuses on medications used to treat high blood pressure. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular diseases. Antihypertensives work by blocking the action of certain hormones, such as angiotensin II, which cause blood vessels to constrict. Common classes of antihypertensives include diuretics, beta blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. The Antihypertensive market is highly competitive, with many large pharmaceutical companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Other companies, such as AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo, also offer antihypertensive medications. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.